Coinfection of Plasmodium vivax and Epstein–Barr virus: case report

Fatih Akin*1, Celebi Kocaoglu1, Ece Selma Solak1, Halil Ozdemir2, Bayram Pektas3, Sukru Arslan4

1Department of Pediatrics, Konya Education and Research Hospital, Konya, Turkey
2Department of Pediatric Infectious Diseases, Konya Education and Research Hospital, Konya, Turkey
3Department of Parasitology, Konya Education and Research Hospital, Konya, Turkey
4Department of Pediatric Nephrology, Konya Education and Research Hospital, Konya, Turkey

ABSTRACT

Malaria is an acute and chronic illness characterized by paroxysms of fever, chills, sweats, fatigue, anemia, and splenomegaly. It is still an important health problem in malaria-endemic countries. Children living in malaria-endemic areas have elevated Epstein–Barr Virus (EBV) loads in the circulation and acute malaria infection leads to increased levels of circulating EBV that are cleared after anti–malaria treatment. There are many reports about the association of Plasmodium falciparum (P. falciparum) malaria and EBV infection. Here we report a case who had coinfection of Plasmodium vivax (P. vivax) malaria and EBV infection. To the best of our knowledge this is the first case indicating the association of P. vivax malaria and EBV infection.

KEYWORDS

Plasmodium vivax, Epstein–Barr virus, Coinfection

1. Introduction

Malaria is an acute and chronic illness characterized by paroxysms of fever, chills, sweats, fatigue, anemia, and splenomegaly. It has played a major role in human history, causing harm to more people than perhaps any other infectious disease. Malaria is of overwhelming importance in the developing world today, with an estimated 300 to 500 million cases and more than 1 million deaths each year. Most malarial deaths occur among infants and young children[1]. It is known that malaria affects EBV persistence as reflected by increased viral replication. Children living in malaria-endemic areas have elevated Epstein–Barr Virus (EBV) loads in the circulation and acute malaria infection leads to increased levels of circulating EBV that are cleared after anti–malaria treatment[2]. Here we report a case of Plasmodium vivax (P. vivax) infection who was followed up with the diagnosis of EBV infection.

2. Case report

A 5–year old Turkish boy from Konya admitted to Konya Education and Research Hospital with a history of fever, chills, and fatigue for six weeks. Fever was high grade up to 40°C and he had fever spikes every other day. There was no history of any cough, vomiting, abdominal pain, joint pain, diarrheae, urinary complaints or drug intake. He had been in Iran for 1 year and had returned to Turkey 2 months ago. He had been followed up with the diagnosis of EBV infection in another hospital.

On admission to our hospital his temperature was 38.8°C. He had a heart rate of 118/min, respiratory rate of 24/min and blood pressure of 110/70 mmHg. Liver was palpable subcostally 2–3 cm and spleen was 2 cm palpable below the left costal margin. Laboratory investigations revealed: hemoglobin 10.4 g/dL, white blood cell count 4310/mm3 (neutrophils 36%, lymphocytes 60%, and monocytes 4%), platelet count 152,000/mm3, sedimentation rate 65 mm/h, and CRP 15.7 mg/L. Thin smear of peripheral blood showed ameboid trophozoites of P. vivax (Figure 1). EBV viral capsid antigen (VCA) IgM, EBV VCA IgG and EBNA IgG was positive and other antibodies against viral pathogens including cytomegalovirus, herpes simplex virus, rubella, toxoplasma, parvovirus B19 and hepatitis A, B, C viruses were negative. Results of the cultures of blood and urine were also negative. Biochemical analysis were within normal levels. Laboratory investigations made at the prior hospital performed

*Corresponding author: Dr. Fatih Akin, Konya Training and Research Hospital, 42400 Meram, Konya, Turkey.
Tel: 00903223237679
Fax: 00903223237623
E–mail: drfatihakin@gmail.com

Article history:
Received 4 Nov 2012
Received in revised form 8 Nov, 2nd revised form 13 Nov, 3rd revised form 17 Nov 2012
Accepted 28 Dec 2012
Available online 28 Feb 2013
20 d ago revealed: hemoglobin 10 g/dL, white blood cell count 5210/mm³, platelet count 128000/mm³, EBV VCA IgM positive and EBV EBNA IgM negative. The diagnosis of EBV infection was made and no medications were given.

Figure 1. Ameboid trophozoite of P. vivax seen on thin smear of peripheral blood.

As we obtained the diagnosis of P. vivax malaria he was treated with chloroquine once orally at 10 mg/kg first dose, followed by 5 mg/kg in three doses over the next 6, 24 and 48 h and primaquine at 0.6 mg/kg in four divided doses a day for 14 d. He was no longer febrile after 2 d of treatment. P. vivax trophozoites were disappeared on peripheral blood smear on the third day of treatment. 1 week after completing the treatment laboratory analysis revealed: hemoglobin 12.8 g/dL, white blood cell count 7780/mm³ and platelet count 164000/mm³.

3. Discussion

P. vivax malaria is an important health problem in malaria-endemic countries. Despite all eradication practices it’s still endemic in the South-east Anatolia and Cukurova regions of Turkey. P. vivax is the most common cause of malaria agent in Turkey with rare P. falciparum and Plasmodium malaria cases. Most of these cases in our country have a history of traveling to malaria-endemic countries[3]. Our patient also had a traveling history to Iran for 1 year.

Semi epidemiological studies have shown that about 91% of the adults worldwide have had first time infection by EBV. In developing countries, first-time infection by EBV is more frequent in the first decade of life[4]. Once EBV infection has occurred, it remains for the lifetime of the individual, making EBV one of the most persistent viruses that infect humans[5]. It is known that malaria affects EBV persistence as reflected by an increased viral replication. Because delay in diagnosis and treatment can result in severe illness or death, earlier diagnosis and prompt treatment of malaria is crucial for prevention of its complications.

Conflict of interest statement

We declare that we have no conflict of interest.

Comments

Background

Epstein–Barr virus establish a life long infection within the human host following primary infection. P. falciparum infection can contribute to EBV reactivation in the blood.

Related reports

Other studies in this area reported that Plasmodium falciparum infection caused increased titers of EBV infection.

Peer review

In this case, authors reported a 5-year old Turkish boy, who had lived in Iran for 1 year and returned to Turkey 2 months ago. They diagnosed co-infection of P. vivax and EBV in the child for the first time. The case is important, because late diagnosis and treatment of malaria in non-endemic regions can cause severe complications of the disease.

References

[1] John CC, Krause PJ. Malaria (Plasmodium). In: Kliegman RM, Stanton BF, Behrman RE, St. Geme JW, Schor NF, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Elsevier Saunders; 2011, p. 1198–1207.
[2] Chêne A, Nylén S, Donati D, Bejarano MT, Kirondo F, Wahlgren M, et al. Effect of acute Plasmodium falciparum malaria on reactivation and shedding of the eight human herpes viruses. PLoS One 2011; 6(10): e26266.
[3] Karahocagil MK, Baran AL, Yaman G, Çiçek M, Bilici A, Binici I, et al. Case report: two Plasmodium vivax malaria cases in the Van Province. Turkiye Parazitol Derg 2009; 33(2): 172–173.
[4] Saldaña NG, Colin VAM, Ruiz GP, Olguín HJ. Clinical and Laboratory characteristics of infectious mononucleosis by Epstein–Barr virus in Mexican children. BMC Res Notes 2012; 5: 361.
[5] Serraino D, Piselli P, Angeletti C, Scuderi M, Ippolito G, Capobianchi MR. Infection with Epstein–Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 2005; 19(1–2): 63–70.
[6] Moormann AM, Snider CJ, Chelino K. The company malaria keeps: how co-infection with Epstein–Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis 2011; 24(5): 435–41.